Endo International plc and Endo Pharmaceuticals Inc. agreed to pay 2.3 million to resolve multistate litigation alleging anti-competitive, "pay-for-delay" conduct related to Endo's sale of Lidoderm, a pain-relief drug that treats complications from shingles.